Home / Categories / HUMALOG KWIK PEN(LISPRO) (100 IU/ML)

HUMALOG KWIK PEN(LISPRO) (100 IU/ML)

HUMALOG KWIK PEN(LISPRO) (100 IU/ML)
(5PENX3ML)

Composition:

INSULIN LISPRO

Group Name:

ULTRA SHORT ACTING INSULIN

Manufacturer:

ELI LILLY AND COMPANY COMPANY P. LTD

Rs 952.31 / PEN
Rs 1023.99 7% off

Product Details

Insulin Lispro

A to Z Drug Facts

Insulin Lispro

Action
Indications
Contraindications
Route/Dosage
Interactions
Lab Test Interferences
Adverse Reactions
PrecautionsPatient Care Considerations
Administration/Storage
Assessment/Interventions
Patient/Family Education

(IN-suh-lin)Humalog, Humalog Mix 75/25, Humalog Mix 50/50Class: Antidiabetic

 Action Regulates proper glucose use in normal metabolic processes.

 Indications

Insulin Aspart: Treatment of patients with diabetes mellitus for the control of hyperglycemia; however, because of rapid onset and short duration of action, insulin aspart should normally be used in regimens that include an intermediate- or long-acting insulin.

Insulin Glargine: Treatment of patients with diabetes mellitus who require long-acting insulin for control of hypoglycemia.

Insulin Lispro: Treatment of patients with diabetes mellitus for control of hyperglycemia. In patients with type 1 diabetes, use in regimens that include a longer-acting insulin. In patients with type 2 diabetes, may be used without longer-acting insulin when used concurrently with sulfonylureas.

 Contraindications During episodes of hypoglycemia; hypersensitivity to any component.

 Route/Dosage

ADULTS: SC Individualized; determined by physician in accordance with patient's needs (usual requirement 0.5 to 1 units/kg/day). ADULTS AND CHILDREN ³ 6 YRS: SC Once daily at bedtime, dose determined by close monitoring under medical supervision during change from a treatment regimen with an intermediate- or long-acting insulin. Insulin Lispro: Type 1 diabetes ADULTS: SC Variable; determined by health care professional. Type 2 diabetes ADULTS AND CHILDREN > 3 YRS (in combination with sulfonylureas): SC Variable; determined by health care professional. ADULTS: SC Variable; determined by health care professional.

 Interactions

Oral contraceptives, corticosteroids, estrogens, isoniazid, niacin, phenothiazines, thyroid hormone: May decrease hypoglycemic effects of insulin lispro. Alcohol, angiotensin-converting enzyme inhibitors, beta blockers, MAO inhibitors, oral hypoglycemic agents, pancreatic function inhibitors (eg, octreotide, salicylates, sulfa antibiotics): May increase hypoglycemic effects of insulin lispro. Beta blockers may mask the symptoms of hypoglycemia in some patients.

 Lab Test Interferences None well documented.

 Adverse Reactions

META: Hypoglycemia; hypokalemia. DERM: Lipodystrophy (from repeated insulin injection into same site). OTHER: Hypersensitivity reaction (eg, rash, shortness of breath, fast pulse, sweating, hypotension, anaphylaxis, angioedema); local reactions (eg, redness, swelling, and itching at injection site).

 Precautions

Pregnancy: Category B (insulin lispro); Category C (insulin aspart, insulin glargine). Lactation: Undetermined. Children: Insulin aspart: Safety and efficacy not establised. Insulin glargine: Safety and efficacy not established in children < 6 yrs with type 1 diabetes. Insulin lispro: In combination with sulfonylureas, safety and efficacy not established in children £ 3 yrs. Insulin lispro mix: Safety and efficacy not established in children £ 18 yrs. Changing insulin: Changes in purity, strength, brand, type, species source, or method of manufacture (rDNA vs animal source) of insulin may necessitate dosage adjustment. Make changes cautiously under medical supervision. Renal/Hepatic impairment: Insulin lispro dose may need to be reduced. Hypoglycemia: May result from excessive insulin dose, missed meals, increased work, or exercise without eating.


PATIENT CARE CONSIDERATIONS

 

 Administration/Storage

  • When mixing insulins, draw insulin lispro into syringe first. Administer immediately after mixing.
  • Do not administer mixtures IV.
  • Use only insulin syringes.
  • Select appropriate injection site according to patient history and needs; rotate injection sites to prevent lipodystrophy. SC insulin lispro is absorbed most rapidly at abdominal injection sites, more slowly at sites on arms, and slowest at sites on anterior thigh.
  • Administer insulin lispro 15 min before meals.
  • Do not freeze. Do not use insulin lispro if previously frozen.
  • Do not expose to extreme temperature or direct sunlight.

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess patient for signs of hypoglycemia (eg, anxiety, chills, confusion, cool and pale skin, drowsiness, excessive hunger, headache, irritability, nausea, rapid pulse, tremors).
  • Observe patient for signs of hyperglycemia (eg, drowsiness, fruitlike breath odor, frequent urination, loss of appetite, thirst).
  • Monitor blood glucose levels throughout course of therapy.
  • Observe injection sites for signs of local hypersensitivity reaction, such as redness, itching, or burning.
  • Notify physician if hypoglycemia or adverse reactions occur.
  • If lipoatrophy or lipohypertrophy develop at injection site, use alternate sites or use purified insulin.
  • Document injection sites used.

OVERDOSAGE: SIGNS & SYMPTOMS Fatigue; weakness; nervousness; confusion; headache; diplopia; convulsions; psychosis; dizziness; unconsciousness; rapid or shallow respiration; numb or tingling mouth; hunger; nausea; skin pallor; moist or dry skin

 Patient/Family Education

  • Teach name, dose, action, and side effects of insulin.
  • Tell patient not to change brand, strength, type, or dose without physician's knowledge.
  • Dosage adjustments may be necessary when type of insulin is changed.
  • Tell patient to consult physician for dosage changes during illness.
  • Instruct patient to use same type and brand of syringe each time to prevent dosage errors.
  • Explain potential long-term complications of diabetes and encourage regular general physical and eye examinations.
  • Tell patient to report redness, swelling, or itching at injection site.
  • Explain significance and importance of reporting the following: Visual changes; rash; infection that does not heal; increased thirst; increased urination; dry mouth; burning sensation in feet, legs, or hands; pain in legs after exercise; frequent episodes of low or high blood sugar levels.
  • Show patient how to rotate injection sites to prevent scarring.
  • Teach patient how to monitor blood glucose as directed.
  • Identify source for obtaining medical ID (eg, Medi-Alert) and explain importance of information.
  • Teach patient and family how to draw up and administer insulin.
  • Demonstrate self-care techniques using insulin pump for patients.
  • Emphasize importance of compliance with diet and exchange system for meals.
  • Emphasize importance of regular exercise.
  • Tell patient to carry source of sugar (eg, candy, sugar packets) to counteract hypoglycemia.

Books@Ovid
Copyright © 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts

 

Substitutes
HUMALOG CARTRIDGE(LISPRO) (100 IU/ML)

HUMALOG CARTRIDGE(LISPRO) (100 IU/ML) 7% off

(5)

Manufacturer: ELI LILLY AND COMPANY COMPANY P. LTD

Rs 1,008.86 / 1CART
Rs 1084.80
+977 9851149866 +977 9851149866 +977 9851149866

Annapurna Pharmacy P. Ltd. announce easy online services to the customer for ordering medicine with home delivery services at fair price.